Please login to the form below
Seattle Generics
This page shows the latest Seattle Generics news and features for those working in and with pharma, biotech and healthcare.
Seattle Genetics signs $2bn deal for Immunomedics' cancer drug
Immunomedics has signed up Seattle Genetics as the licensee for its triple-negative breast cancer (TNBC) drug IMMU-132, getting $300m upfront and another $1.7bn in possible milestone payments. ... Seattle Genetics will handle the running of a proposed
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
PMHub
fox&cat
Fox&cat is a new kind of fully-integrated communications agency – one that delivers genuinely inspirational campaigns and programmes with equal...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
